Compare Stocks

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IN InMed Pharmaceuticals		C$4.19	C$3.35 ▼ C$13.86	C$33.73M	N/A	29,552 shs	17,035 shs
NDVA Indiva	C$0.06	C$0.08	C$0.02 ▼ C$0.13	C$11.72M	1.11	101,417 shs	8,887 shs
VIR Vir Biotechnology	$7.96 -3.5%	$10.14	$7.72 ▼ $27.48	$1.11B	0.41	719,406 shs	1.07 million shs
ZOM Zomedica	$0.13	$0.00	$0.12 ▼ $0.25	$127.69M	1	3.96 million shs	2.63 million shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IN InMed Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
NDVA Indiva	0.00%	+9.09%	-25.00%	-42.86%	-20.00%
VIR Vir Biotechnology	-3.52%	-13.85%	-20.40%	-16.12%	-68.29%
ZOM Zomedica	0.00%	0.00%	+1.67%	+4.23%	-33.73%

Now Open: Crypto emergency update (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IN InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NDVA Indiva	1.5529 of 5 stars	3.5	0.0	1.7	0.0	0.6	2.5	0.0
VIR Vir Biotechnology	2.5816 of 5 stars	3.3	3.0	0.0	0.0	1.1	3.3	1.3
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IN InMed Pharmaceuticals	N/A	N/A	N/A	N/A
NDVA Indiva	3.00	Buy	C$0.15	150.00% Upside
VIR Vir Biotechnology	2.57	Moderate Buy	$34.38	331.85% Upside
ZOM Zomedica	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest IN, VLG, ZOM, VIR, and NDVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/15/2024	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00
2/23/2024	VIR Vir Biotechnology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$9.00 ➝ $10.00
2/14/2024	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $110.00
1/29/2024	VIR Vir Biotechnology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$23.00 ➝ $9.00
1/23/2024	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$95.00 ➝ $85.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IN InMed Pharmaceuticals	C$574.68K	0.00	N/A	10.40	C$0.76 per share	0.00
NDVA Indiva	C$36.01M	0.33	C$0.01 per share	5.20	N/A	∞
VIR Vir Biotechnology	$86.18M	12.42	N/A	N/A	$11.82 per share	0.67
ZOM Zomedica	$25.19M	5.03	N/A	N/A	$0.24 per share	0.54

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IN InMed Pharmaceuticals	N/A	-C$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NDVA Indiva	-C$6.94M	-C$0.05	N/A	∞	N/A	-19.27%	-288.64%	-6.91%	5/14/2024 (Estimated)
VIR Vir Biotechnology	-$615.06M	-$4.59	N/A	N/A	N/A	-713.69%	-34.92%	-27.73%	5/2/2024 (Confirmed)
ZOM Zomedica	-$34.53M	-$0.04	N/A	∞	N/A	-137.10%	-8.13%	-7.68%	5/9/2024 (Estimated)

Latest IN, VLG, ZOM, VIR, and NDVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/2/2024	N/A	VIR Vir Biotechnology	-$0.99	N/A	+$0.99	N/A	N/A	N/A
4/1/2024	Q4 2023	ZOM Zomedica	N/A	-$0.01	-$0.01	N/A	$7.00 million	$7.34 million
2/22/2024	Q4 2023	VIR Vir Biotechnology	-$1.14	-$0.86	+$0.28	-$0.86	$11.18 million	$16.80 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IN InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NDVA Indiva	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IN InMed Pharmaceuticals	8.48	2.13	1.45
NDVA Indiva	5,899.22	0.85	0.52
VIR Vir Biotechnology	N/A	9.05	9.05
ZOM Zomedica	N/A	11.06	10.49

Ownership

Institutional Ownership

Company	Institutional Ownership
IN InMed Pharmaceuticals	N/A
NDVA Indiva	0.33%
VIR Vir Biotechnology	65.32%
ZOM Zomedica	8.95%

Insider Ownership

Company	Insider Ownership
IN InMed Pharmaceuticals	N/A
NDVA Indiva	36.29%
VIR Vir Biotechnology	18.10%
ZOM Zomedica	4.18%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
IN InMed Pharmaceuticals	12	8.05 million	N/A	Not Optionable
NDVA Indiva	147,000	195.30 million	N/A	Not Optionable
VIR Vir Biotechnology	587	134.50 million	110.16 million	Optionable
ZOM Zomedica	144	979.95 million	938.99 million	Not Optionable

IN, VLG, ZOM, VIR, and NDVA Headlines

Source	Headline
	Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024 accesswire.com - April 9 at 6:30 AM
	Zomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call Transcript msn.com - April 2 at 4:06 PM
	Q4 2023 Zomedica Corp Earnings Call finance.yahoo.com - April 2 at 8:30 AM
	ZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023 investorplace.com - April 1 at 9:06 PM
	Zomedica reports Q4 results msn.com - April 1 at 5:27 PM
	Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity accesswire.com - April 1 at 4:05 PM
	The Next Millionaire-Makers: 3 Penny Stocks With Massive Upside Potential investorplace.com - April 1 at 3:12 PM
	Zomedica to Report Fourth Quarter and Full Year 20… pharmiweb.com - March 20 at 9:17 AM
	Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET accesswire.com - March 20 at 6:30 AM
	Zomedica Pharmaceuticals Corp (ZOM) investing.com - March 15 at 7:52 AM
	Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform accesswire.com - March 14 at 6:30 AM
	Zomedica Provides NYSE American Listing Update accesswire.com - March 13 at 4:45 PM
	Sidoti & Company, LLC: Sidoti Events, LLC's Virtual March Small-Cap Conference finanznachrichten.de - March 12 at 11:26 AM
	Zomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences finanznachrichten.de - March 12 at 8:22 AM
	Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences accesswire.com - March 12 at 6:30 AM
	Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs accesswire.com - March 7 at 6:30 AM
	Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024 accesswire.com - March 5 at 6:30 AM
	Zomedica Pharmaceuticals Corp. (ZOM) uk.finance.yahoo.com - March 1 at 2:46 PM
	Zomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences finanznachrichten.de - February 8 at 9:14 AM
	Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences finance.yahoo.com - February 8 at 9:14 AM
	Zomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation finanznachrichten.de - February 6 at 5:00 PM
	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split) finance.yahoo.com - February 6 at 5:00 PM
	Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET finance.yahoo.com - February 6 at 7:00 AM
	Zomedica Corp. (ZOM) Interactive Stock Chart - Yahoo Finance finance.yahoo.com - February 4 at 8:05 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
April 3, 2024 6:20 AM
View Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill

All Headlines

Company Descriptions

InMed Pharmaceuticals

TSE:IN

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Indiva

CVE:NDVA

Indiva Limited engages in the production, processing, and sale of cannabis and cannabis related products in Canada. It offers pre-rolls, flower, capsules, and edible and extract products under the INDIVA, Indiva Life, and Artisan Batch brands. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Jewels Chewable Tarts, Grön edibles, and Dime Industries vape products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.

Vir Biotechnology

NASDAQ:VIR

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Zomedica

NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial